Cost-effectiveness analysis in BRAF(V600E) metastatic melanoma finds dabrafenib more efficient than vemurafenib

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

A recent study evaluated the cost-effectiveness of BRAF inhibitors and traditional chemotherapy for the treatment of metastatic melanoma. Results suggest that compared with dacarbazine, dabrafenib and vemurafenib were not cost-effective at a willingness-to-pay threshold of $100,000/QALY. Dabrafenib was also found to be more efficient compared to vemurafenib. 


  • A Markov model was developed using a societal perspective
  • Transition probabilities were derived from two Phase III registration trials comparing each BRAF inhibitor against dacarbazine
  • Costs were obtained from literature, national databases, and Med...